At $850,000, price for new childhood blindness gene therapy four times too high, analysis says
Luxturna, a gene therapy with a list price $850,000, is the latest flashpoint in the debate over how to afford innovative medicines.
We may soon have our first $1 million drug. Who will pay for it? And how?
As the first gene therapies approach the market, drug makers, insurers, and patients are debating complex questions about cost, value, and payment plans.
U.S. clears first ‘gene therapy’ for tough childhood leukemia
Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia.
Watch
Mapping the Genomes of Crocodiles and Alligators
Science Nation video mapping genomes of alligators crocodiles and bats…
Dr. Kathy Zoon of the federal Food and Drug Administration oversees the roughly 200 gene therapy clinical trials now underway in the United States.
